Aino Latva‐Rasku

The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients

Aino Latva‐Rasku, Miikka‐Juhani Honka, Joel Kullberg et al. · Diabetes Care · 2019 · 235 citations · Full text

Insulin-stimulated glucose uptake in skeletal muscle, adipose tissue and liver: a positron emission tomography study

Miikka‐Juhani Honka, Aino Latva‐Rasku, Marco Bucci et al. · European Journal of Endocrinology · 2018 · 128 citations · Full text

Insulin Resistance Is Associated With Enhanced Brain Glucose Uptake During Euglycemic Hyperinsulinemia: A Large-Scale PET Cohort

Eleni Rebelos, Marco Bucci, Tomi Karjalainen et al. · Diabetes Care · 2021 · 64 citations · Full text

Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlled, exploratory study

Jonas Oldgren, Sanna Laurila, Axel Åkerblom et al. · Diabetes Obesity and Metabolism · 2021 · 61 citations · Full text

A Partial Loss-of-Function Variant in <i>AKT2</i> Is Associated With Reduced Insulin-Mediated Glucose Uptake in Multiple Insulin-Sensitive Tissues: A Genotype-Based Callback Positron Emission Tomography Study

Aino Latva‐Rasku, Miikka‐Juhani Honka, Alena Stančáková et al. · Diabetes · 2017 · 45 citations · Full text